论文部分内容阅读
目的:研究家蚕表达重组人乳铁蛋白及其口服治疗溃疡性结肠炎的药物治疗效果。方法:选取我院2013年10月-2014年11月间诊治的溃疡性结肠炎患者110例,将其随机分为观察组和对照组各55例,对观察组患者采用家蚕表达重组人乳铁蛋白及其口服方式治疗,对对照组患者采用柳氮磺胺吡啶治疗,对比观察两组患者的临床治疗效果及不良反应。结果:观察组患者的总有效率为94.55%,对照组患者的总有效率为80.00%,观察组明显高于对照组,差异具有统计学意义(P<0.05);在不良反应发生率方面,观察组患者为9.09%,对照组患者为21.82%,观察组明显低于对照组,差异具有统计学意义(P<0.05)。结论:采用家蚕表达重组人乳铁蛋白及其口服治疗溃疡性结肠炎不仅可以显著提高临床治疗效果,而且还能降低不良反应的发生率,值得临床推广使用。
Objective: To study the therapeutic effect of silkworm recombinant human lactoferrin and its oral treatment on ulcerative colitis. Methods: A total of 110 patients with ulcerative colitis who were diagnosed and treated in our hospital from October 2013 to November 2014 were randomly divided into observation group (55 cases) and control group (55 cases). The observation group was treated with silkworm recombinant human lactoferrin Protein and its oral treatment, the control group of patients treated with sulfasalazine, the two groups were observed and compared the clinical effects and adverse reactions. Results: The total effective rate was 94.55% in the observation group and 80.00% in the control group, the observation group was significantly higher than the control group (P <0.05); in the incidence of adverse reactions, The observation group was 9.09%, the control group was 21.82%, the observation group was significantly lower than the control group, the difference was statistically significant (P <0.05). Conclusion: Recombinant human lactoferrin expressed in silkworms and its oral treatment of ulcerative colitis can not only significantly improve the clinical treatment effect, but also reduce the incidence of adverse reactions, it is worth promoting the use of clinical.